According to a consortium member, "crystal polymorphism is a key risk factor for drug product manufacturing and performance and remains one of the major problems encountered in drug development. The CSD Solid Form Suite with its newly-developed Hydrogen Bond Propensity tool will help scientists to quantify the risk of polymorphism allowing them to make informed decisions on which crystalline form to develop. This tool, applied to known crystal structures and even 2D renditions of a molecular structure, is sure to advance the experimental screening and selection of drug crystal forms, the first step towards ensuring Quality is built by Design into drug products."
The CSD Solid Form Suite will be generally available at the end of November 2011 as part of the forthcoming 2012 release of the CSD System. For more information on the CSD Solid Form Suite, visit http://www.ccdc.cam.ac.uk/products/csd_solid_form_suite